Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Wessner

Internal Medicine Dothan, AL Medical Doctor

NPI 1497723423 CMS profile 248962

2115 W Main St, Dothan, AL 36301

Open in the dashboard

General payments

$12,004

750 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Wessner of Dothan, AL is reported in the CMS Open Payments database as having received $12,004 across 750 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,347 83
2024 General $1,412 87
2023 General $1,835 117
2022 General $2,098 120
2021 General $2,071 137
2020 General $1,696 101
2019 General $1,545 105

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Wessner
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to John Wessner were reported at $1,347. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year John Wessner Internal Medicine median Middle half National median
2019 $1,545 $159 $48–$570 $163
2020 $1,696 $119 $33–$402 $114
2021 $2,071 $135 $37–$521 $132
2022 $2,098 $141 $42–$496 $149
2023 $1,835 $149 $45–$519 $160
2024 $1,412 $154 $47–$537 $164
2025 $1,347 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $1,408 105 payments
  2. Novo Nordisk Inc $1,260 103 payments
  3. Astellas Pharma US Inc $1,183 51 payments
  4. Pfizer Inc. $919 57 payments
  5. Amgen Inc. $732 41 payments
  6. AstraZeneca Pharmaceuticals LP $702 45 payments
  7. Amarin Pharma Inc. $625 33 payments
  8. GlaxoSmithKline, LLC. $613 37 payments
  9. Novartis Pharmaceuticals Corporation $579 39 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $565 30 payments
  11. Other $3,417 209 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,656 740 payments
  2. Education $348 10 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,070 89 payments
  2. RYBELSUS $937 79 payments
  3. MOUNJARO $744 51 payments
  4. MYRBETRIQ $667 37 payments
  5. ELIQUIS $653 37 payments
  6. Kerendia $565 30 payments
  7. Vascepa $514 24 payments
  8. TRELEGY ELLIPTA $505 28 payments
  9. TRULICITY $499 43 payments
  10. JARDIANCE $495 42 payments
  11. Other $9,449 619 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 204 drugs

Part D claims

17,072

Median for Internal Medicine: 777

Drug cost

$1,568,088

Median for Internal Medicine: $73,373

Branded share of claims

23%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 201 $278,138
Eliquis Apixaban Brand 210 $229,193
Farxiga Dapagliflozin Propanediol Brand 86 $95,446
Jardiance Empagliflozin Brand 64 $83,473
Mounjaro Tirzepatide Brand 70 $83,432
Trulicity Dulaglutide Brand 50 $67,614
Januvia Sitagliptin Phosphate Brand 54 $65,294
Rybelsus Semaglutide Brand 44 $60,192
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 40 $54,599
Tresiba Flextouch U-200 Insulin Degludec Brand 44 $45,466

The 10 drugs with the highest cost, of 204 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$209,804

Of which drugs: $16,770

Medicare patients

517

Average age 76

Services billed

4,678

277 women, 240 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 33%
Ischemic heart disease 30%
COPD 24%
Atrial fibrillation 23%
Chronic kidney disease 18%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 172 174 $14,197
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 57 212 $176
Injection, ketorolac tromethamine, per 15 mg J1885 Office 85 330 $152
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 127 185 $14

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
$146 70 —
TRELEGY ELLIPTA
$127 40 —
ELIQUIS
$102 210 —
JARDIANCE
$70 64 —
REXULTI
$68 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

750 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record